Antitumour responses, measured by ORR, radiologic response, or tumour-marker response, were reported in early studies of women with previously treated and advanced BC or OC.55–57 Later, an open-label, single-arm phase II basket study reported results for olaparib monotherapy in 62 women with BRCA1/2m-related advanced BC.58 These patients were heavily pretreated, with a mean of 4.6 chemotherapy regimens in the metastatic setting, including 42 (68%) who had received prior platinum therapy (cisplatin or carboplatin). Here, BRCA1 is linked to breast cancer.